Mgenst Cell Engager Shows Phase Ii Promise In Tough To Treat Lung Cancer News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Tarlatamab achieved a 40% objective response rate in small cell lung cancer patients with advanced disease who had failed two or more prior lines of treatment, the company announced Friday.

United statesDavid reeseBoehringer ingelheimEuropean society for medical oncology congressEuropean societyMedical oncology congressNew england journalFast track designationMgenst cell engager shows phase ii promise in tough to treat lung cancer